H.R. 1796

119th CONGRESS 1st Session

To amend the Public Health Service Act to reauthorize a sickle cell disease prevention and treatment demonstration program.

IN THE HOUSE OF REPRESENTATIVES · March 3, 2025 · Sponsor: Mr. James · Committee: Committee on Energy and Commerce

Table of contents

• H.R. 1796
  • SEC. 1. Short title
  • SEC. 2. Sickle cell disease treatment prevention and treatment

SEC. 1. Short title

• This Act may be cited as the Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025.

SEC. 2. Sickle cell disease treatment prevention and treatment

• (a) In general
  • Section 1106(b) of the Public Health Service Act () is amended— 42 U.S.C. 300b–5(b)
  • In general
    • in paragraph (1)(A)(iii), by striking prevention and treatment of sickle cell diseaseand inserting treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease;
    • in paragraph (2)(D), by striking prevention and treatment of sickle cell diseaseand inserting treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease;
    • in paragraph (3)—
      • in subparagraph (A), by striking enter into a contract withand inserting make a grant to, or enter into a contract or cooperative agreement with,; and
      • in subparagraph (B), in each of clauses (ii) and (iii), by striking prevention and treatment of sickle cell diseaseand inserting treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease; and
    • in paragraph (6), by striking $4,455,000 for each of fiscal years 2019 through 2023and inserting $8,205,000 for each of fiscal years 2025 through 2029.
• (b) Sense of Congress
  • It is the sense of Congress that further research should be undertaken to expand the understanding of the causes of, and to find cures for, heritable blood disorders, including sickle cell disease.